Viamune is structured around investigating related tumor-associated glycoproteins to expand the firm's drug therapy pipeline. Offering a fully synthetic vaccine platform that generates robust immune responses to tumor-specific targets, tViamune's patented technology provides a unique path to targeting structures found only on tumor cells. The company is developing an immunotherapy vaccine targeting tumor-specific MUC1, a cell-surface glycoprotein designed to help cancerous cells form a barrier against chemotherapeutic drugs. ViaMunes lead compound MTI, still in the pre-clinical stage promises to target aberrant MUC1 specifically and to defeat tolerance to tumor antigens - therebyaiding in tumor treatmen